ReviewiScience2025
Neurodegeneration rewires the tumor microenvironment via the neuro-immune-cancer axis.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Emerging New Pathways in Malignant Neoplasms and Neurodegenerative Disorders: Perspectives for Therapeutics.Cells · 2026Review
- Circadian engineering of in vivo CAR T cell therapy for precision oncology.NPJ precision oncology · 2026Review
- Mitophagy-driven multidimensional regulation of tumor immune evasion and context-dependent therapeutic strategies.Journal of translational medicine · 2026Review
- Gut microbiome-driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming.NPJ biofilms and microbiomes · 2026Review
- Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.Journal of immunology research · 2026Review
- T cell exhaustion landscapes and therapeutic modulation in cancer immunity.Frontiers in cell and developmental biology · 2026Review
- Vaccination-enabled immune readiness for checkpoint blockade.Frontiers in immunology · 2026Review
- Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer.Frontiers in cell and developmental biology · 2026Review
- Decoding the microbial blueprint of pancreatic cancer.Frontiers in medicine · 2026Review
- Biohacking the human gut microbiome for precision health and therapeutic innovation.Frontiers in microbiology · 2026Review
- The hallmarks of neuro-immune reprogramming in cancer.Frontiers in immunology · 2026Review
- The microbiome-gerogene axis: a new frontier in precision geromedicine.Frontiers in aging · 2026Review
- Cross-Disciplinary Mechanistic Insights in Molecular Medicine.Current issues in molecular biology · 2025Article
- Vitamin D Associated with Exercise Can Be Used as a Promising Tool in Neurodegenerative Disease Protection.Molecules (Basel, Switzerland) · 2025Review
- Chronobiome medicine: circadian regulation of host-microbiota crosstalk in systemic physiology.Frontiers in endocrinology · 2025Review
- Neurotrophin NGF/TrkA and BDNF/TrkB signaling orchestrates the immune microenvironment in osteosarcoma.Frontiers in immunology · 2025Review
- The gut-brain-circadian axis in anxiety and depression: a critical review.Frontiers in psychiatry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegeneration and cancer, long considered opposing processes, neuronal loss versus uncontrolled proliferation, are increasingly recognized as mechanistically convergent. This review reframes the field by positioning neurodegeneration as an active driver of tumor evolution. Integrating insights from multi-omics, spatial transcriptomics, and neuroimmune-microbiota studies, we show how degenerating neurons disrupt DNA repair, mitochondrial function, immune regulation, and barrier integrity, thereby creating tumor-permissive niches. Particular emphasis is placed on the enteric nervous system, where neuronal loss promotes colorectal and pancreatic cancers through immune suppression and microbial dysbiosis. Shared molecular regulators, including p53, Pin1, STING, and the Biglycan-IL-10-microbiota axis, exhibit dual roles, pro-apoptotic in neurons yet pro-survival in tumors, highlighting context-dependent biology. We propose a mechanistic, target-based therapeutic classification that transcends disease boundaries. Recognizing neurodegeneration as a tumor-promoting process uncovers novel diagnostic and therapeutic opportunities, expanding cancer neuroscience beyond its current paradigm.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.